Breast Cancer: Current Perspectives on the Disease Status

2019 ◽  
pp. 51-64 ◽  
Author(s):  
Mohammad Fahad Ullah
Keyword(s):  
Breast Cancer ◽  
Disease Status

scholarly journals Factors Associated with Metastatic Breast Cancer in Patients Who Show Long-Term Stable Disease Status

2017 ◽  
Vol 5 (1) ◽  
pp. 1-7
Author(s):  
Young Hoon Noh ◽  
Yun Gyoung Kim ◽  
Ji Hyun Kim ◽  
Hyang Suk Choi ◽  
Seok Joon Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Stable Disease ◽  
Metastatic Breast ◽  
Disease Status ◽  
Factors Associated

Breast cancer in the elderly.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11506-e11506
Author(s):  
Dilek Erdem ◽  
Bahiddin Yilmaz ◽  
Fatih Mehmet Cilingir ◽  
Selim Kocasarac ◽  
Fatih Teker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Elderly Women ◽  
Ductal Carcinoma ◽  
Disease Status ◽  
The Elderly ◽  
Breast Cancer Patients ◽  
Abdominal Ultrasonography ◽  
Age Related ◽  
Patient Decision

e11506 Background: Breast cancer is one of the age-related tumors that accompany with population ageing and approximately 50 % of this disease occur in 65 years of age or older and also more than 30 % occur after age of 70. This study aims to examine characteristics of patients with breast cancer 65 years or older. Methods: The study was carried out on a series of 177 breast cancer patient followed up at our outpatient clinic who are 65 years or older chosen among 848 breast cancer patients during the period 1995-2012. Physical examination, annual chest x-ray, mammography, abdominal ultrasonography and bone scan were the tools to assess the disease status. SPSS 16 was used. Results: The mean age was 70.8 years old (range 65-85 years). There was only one patient whose age is older than 85 years. 85 % of histopathology was infiltratif ductal carcinoma. 83 % of patients underwent mastectomy while 92 % was performed axillary dissection. 56 % had node positivity and 54 % had 2 cm or bigger tumor. ER/PR status was both negative in 54 women (30 %) and both positive in 82 of them. Also cerbB2 was negative in most of the patients (70 %). At the diagnosis, 20 patients (11.3 %) had metastatic disease and 157 were without metastases. Totally 44 patients (32 %) had metastatic disease and most of them (29 patients) had bone disease. Only 52 did not have endocrine therapy with 48 % had tamoxifen as a part of hormonal therapy. Most of them received radiotherapy (54 %). DFS was within 7-182 months with a median of 54 months. PFS was between 2-60 months and patients had a median OS about 61 months. 30 patients died because several causes owing to ageing causes. Conclusions: Breast cancer is the most significant cancer of women and the screening modalities with adjuvant postoperative therapies have increased survival. Acute and chronic medical conditions, nutritional status, poly-pharmacy, level of activity, disease-spesific symptoms and patient decision all need to be taken into consideration. Both in early and advanced stages of the disease, quality of life and related aspects have critical importance in elderly women who have more limited life-expectancy. It is also essential that women with breast cancer 65 years and older be included in trials and that they be recommended the best therapies available.

scholarly journals Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?

2008 ◽  
Vol 2008 ◽  
pp. 1-5
Author(s):  
Carsten Nieder ◽  
Kirsten Marienhagen ◽  
Astrid Dalhaug ◽  
Jan Norum
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Active Treatment ◽  
Systemic Treatment ◽  
Recursive Partitioning ◽  
Survival Rates ◽  
Whole Brain Radiotherapy ◽  
Disease Status ◽  
New Drugs ◽  
Breast Cancer Patients

Newly developed systemic treatment regimens might lead to improved survival also in the subgroup of breast cancer patients that harbour brain metastases. In order to examine this hypothesis, a matched pairs analysis was performed that involved one group of patients, which were treated after these new drugs were introduced, and one group of patients, which were treated approximately 10 years earlier. The two groups were well balanced for the known prognostic factors age, KPS, extracranial disease status, and recursive partitioning analysis class, as well as for the extent of brain treatment. The results show that the use of systemic chemotherapy has increased over time, both before and after the diagnosis of brain metastases. However, such treatment was performed nearly exclusively in those patients with brain metastases that belonged to the prognostically more favourable groups. Survival after whole-brain radiotherapy has remained unchanged in patients without further active treatment. It has improved in prognostically better patients and especially patients that received active treatment, where the 1-year survival rates have almost doubled. As these patient groups were small, confirmation of the results in other series should be attempted. Nevertheless, the present results are compatible with the hypothesis that improved systemic therapy might contribute to prolonged survival in patients with brain metastases from breast cancer.

scholarly journals Breast Cancer Patients’ Treatment Choices and Outcomes in a Naturopathic Clinic

2017 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Breast Cancer Survivors ◽  
Disease Status ◽  
Tumor Burden ◽  
Water Soluble ◽  
Breast Cancer Patients ◽  
Treatment Choices ◽  
History Of

In this study we gathered data in July 2016 by means of questionnaires from breast cancer survivors following initial consult in a naturopathic clinic. Most patients surveyed had previously or concurrently had total surgical resection of their tumor burden, followed by at least 36 treatments of intravenous nutrients, including water -soluble vitamins and minerals. We compare those having a history of surgery with those not having that history. We also compare outcomes among those having a history of radiation therapy and those without, as well as those having a history of chemotherapy and those without. Some of those in remission chose to return for follow-up intravenous nutrients once per month after achieving remission from their cancers. We compare the different cohorts, among the various stages of cancer, for treatment choices and disease status. 97 total cancer survivors responded fully and promptly to the questionnaires. 37 of those were breast cancer patients.

scholarly journals An evaluation of the risk factors of breast cancer in women in Ilam Province: a case–control study based on hospital

2020 ◽  
pp. BMT49
Author(s):  
Shoboo Rahmati ◽  
Milad Azami ◽  
Zahra Jaafari ◽  
Nasrin Pouratar ◽  
Khairollah Asodollahi
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Case Control Study ◽  
Menopausal Status ◽  
Oral Contraceptive Pill ◽  
Disease Status ◽  
Case Control ◽  
Case Group ◽  
History Of ◽  
Control Study

Aims: The present study aimed to identify the most associated risk factors of breast cancer in Ilam province in 2015–2016. Materials & methods: In this case–control study, the case group consisted of 50 women with breast cancer with a definitive diagnosis from date 23 September 2015 to 22 September 2016. The two groups were group matched in terms of age. Data were collected through interviews and medical records. Results: According to the results, there was a significant relationship between the disease status and variables of family history, history of irregular menstrual cycles, history of breastfeeding, menopausal status, history of oral contraceptive pill consumption, BMI, menarche and number of pregnancies (p < 0.05). Conclusion: Regarding decisive risk factors of breast cancer, more studies with larger sample sizes that take into account more risk factors are necessary.

Diagnostic accuracy of the Videssa protein-based liquid biopsy for breast cancer in suspicious mammography.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13034-e13034 ◽  
Author(s):  
Cynthia Chen ◽  
Lisa Poole ◽  
Lina Sizer ◽  
W. Bradford Carter ◽  
Thomas G. Frazier
Keyword(s):  
Breast Cancer ◽  
Predictive Value ◽  
Liquid Biopsy ◽  
Blood Test ◽  
Disease Status ◽  
Tumor Grade ◽  
Invasive Cancer ◽  
Tissue Biopsy ◽  
Solid Lesions

e13034 Background: The Videssa protein-based blood test (Provista Diagnostics) is a combined proteomic biomarker assay that aims to detect established breast cancer – rendering it useful in patients with abnormal or difficult-to-interpret mammograms. Since the incidence of malignancy for BI-RADS 4 biopsies is approximately 20%, a significant percentage of patients undergo needle biopsy unnecessarily. The Videssa assay provides an alternative diagnostic method by way of a non-invasive liquid biopsy. Methods: Our goal was to assess whether this liquid biopsy combined with 3D tomographraphic mammography could accurately predict disease status to reduce the amount of unnecessary tissue biopsies. An IRB-approved, prospective, single-arm study had patients with BI-RADS4 lesions with calcifications requiring tissue biopsy undergo the blood test prior to stereotactic core biopsy. Subsequent results and biopsy pathology were correlated. Results: 46 patients were initially entered with BI-RADS4 calcifications. 9 patients had DCIS (19.6%) and 37 patients had benign calcifications (80.4%). No patient had invasive cancer. Liquid biopsy results were elevated in 2 patients with DCIS (22% sensitivity) and in 5 patients with benign biopsies (10.8%). At interim analysis, the liquid biopsy demonstrated a 28.5% positive predictive value (PPV) and 82% negative predictive value (NPV). Tumor grade did not affect results. We subsequently discontinued using the blood test for BI-RADS4 calcifications and enrolled 13 patients with non-palpable solid lesions to determine the correlation. The liquid biopsy was elevated in 1 of 4 patients with invasive cancer (25% sensitivity) and was not elevated in all 9 patients with benign biopsies (100% NPV). At one-year follow-up, 3 of the 5 patients with an elevated blood assay and negative biopsy have had no incidence of cancer on subsequent imaging. The remaining 2 patients are scheduled for follow-up. Conclusions: In our study, the NPV of the Videssa liquid biopsy is not robust enough to defer tissue biopsy in any patient with indeterminate calcifications on imaging, nor is it specific enough to help predict results in high risk solid lesions. We do not see this liquid biopsy changing our current practice.

Discordance in clinical versus pathological staging in breast cancer: Are we undermining the significance of accurate preoperative staging in the present era?

2021 ◽  
pp. 1-7
Author(s):  
Shina Goyal ◽  
Linu Abraham Jacob ◽  
D. Lokanatha ◽  
M.C. Suresh Babu ◽  
K.N. Lokesh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Preoperative Staging ◽  
Metastatic Breast ◽  
Disease Status ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Chi Square ◽  
Pathological Staging

BACKGROUND: The present era of individualized treatment for breast cancer is influenced by the initial disease status including the anatomical extent, grade, and receptor status. An accurate preoperative staging is the basis of treatment planning and prognostication. Our study aims to determine the discordance between the preoperative clinical and the postoperative pathological stages of breast cancer patients. METHODOLOGY: The medical records of all non-metastatic breast cancer patients from January 2017 to December 2018 who underwent upfront surgery were reviewed. They were staged as per the eighth AJCC and the concordance between the clinical (c) and pathological T (tumor), N (nodal), and final AJCC stage was studied. A Chi-square test was used to determine factors that significantly correlate with disease discordance. RESULTS: A total of 307 breast cancer patients were analyzed. Among these, 43.3% were hormone receptor-positive, 30.6% were Her2 positive and 26% were triple-negative. Overall stage discordance was seen in 48.5% (n = 149) patients (upstaging in 22.1%, downstaging in 26.4%). The discordance rate was 48.9% for T stage (cT versus pT) and 57.4% for N stage (cN versus pN). Among patients with clinically node-negative disease, 53.4% were found to have positive nodes on histopathology, while 27.2% had vice versa. Overall, the factors associated with upstaging were ER-positive, Her2 positive and triple-negative status (all p < 0.05), while none of the factors showed significant association with downstaging. CONCLUSIONS: About half of breast cancer patients had discordance between clinical and pathological staging with higher discordance in the nodal stage. This changes the disease prognosis, and may also affect the offered surgical treatment and radiotherapy. Thus highlighting the need for a precise pre-operative staging. Also, this information will aid clinicians in discussions with patients, keeping in mind the likelihood of change in disease staging and management. 

scholarly journals Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

2009 ◽  
Vol 27 (31) ◽  
pp. 5153-5159 ◽  
Author(s):  
Minetta C. Liu ◽  
Peter G. Shields ◽  
Robert D. Warren ◽  
Philip Cohen ◽  
Mary Wilkinson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Disease Progression ◽  
Endocrine Therapy ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Disease Status ◽  
Radiographic Disease

PurposeFive or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging.Patients and MethodsSerial CTC levels were obtained in patients starting a new treatment regimen for progressive, radiographically measurable MBC. Peripheral blood was collected for CTC enumeration at baseline and at 3- to 4-week intervals. Clinical outcomes were based on radiographic studies performed in 9- to 12-week intervals.ResultsSixty-eight patients were evaluable for the CTC-imaging correlations, and 74 patients were evaluable for the PFS analysis. Median follow-up was 13.3 months. A statistically significant correlation was demonstrated between CTC levels and radiographic disease progression in patients receiving chemotherapy or endocrine therapy. This correlation applied to CTC results obtained at the time of imaging (odds ratio [OR], 6.3), 3 to 5 weeks before imaging (OR, 3.1), and 7 to 9 weeks before imaging (OR, 4.9). Results from analyses stratified by type of therapy remained statistically significant. Shorter PFS was observed for patients with five or more CTCs at 3 to 5 weeks and at 7 to 9 weeks after the start of treatment.ConclusionWe provide, to our knowledge, the first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.

Sign in / Sign up

Export Citation Format

Share Document